Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Green Cross Says It Secured Korea's Largest-ever Agreement For Finished Product Export

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korean vaccine producer Green Cross said it signed a three-year $480 million memorandum of understanding with ASD Healthcare of the U.S. to export intravenous immunoglobulin and hemophilia type A treatment GreenGene-F to the U.S, which would be the country's largest-ever agreement for finished drugs

You may also be interested in...



Korea’s Green Cross Anticipates Growth In Upcoming Flu Season

The upcoming flu season should provide more momentum to Korea’s leading vaccine company, which saw marginal year-on-year growth in the second quarter.

Green Cross Is Latest Korean Pharma To Struggle Under Regulatory Headwinds

SEOUL - Green Cross Corp. has continued a trend among Korean pharma companies by posting relatively sluggish second quarter results

Green Cross Is Latest Korean Pharma To Struggle Under Regulatory Headwinds

SEOUL - Green Cross Corp. has continued a trend among Korean pharma companies by posting relatively sluggish second quarter results

UsernamePublicRestriction

Register

PS141439

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel